Akron、OHにおける非小細胞肺癌の臨床試験
Akronとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する22件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Cleveland Clinic Akron General, Akron
- Aultman Health Foundation, Canton · 21マイル先
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
被験者募集中第3相
- Aultman Health Foundation, Canton · 21マイル先
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
被験者募集中第3相
- Akron General Medical Center, Akron
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- Aultman North, North Canton · 15マイル先
- Aultman Massillon, Massillon · 20マイル先
- Aultman Orrville Hospital, Orrville · 21マイル先
- 他2件
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
被験者募集中第3相
- Research Site, Canton · 21マイル先
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
被験者募集中第3相
- Aultman Hospital, Canton · 21マイル先
Pan-tumor MRD Study
被験者募集中観察研究
- Gabrail Cancer Center, Canton · 21マイル先
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
被験者募集中第2/3相
- Gabrail Cancer Center Research, Canton · 21マイル先
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
被験者募集中第2相
- Gabrail Cancer Center, Canton · 21マイル先
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
被験者募集中第2/3相
- Tricounty Hematology and Oncology - Massillon, Massillon · 20マイル先
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
被験者募集中第1/2相
- Gabrail Cancer Center Research, Canton · 21マイル先
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
被験者募集中第3相
- Gabrail Cancer Center, Canton · 21マイル先
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
被験者募集中第2相
- Gabrail Cancer and Research Center, Canton · 21マイル先
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
被験者募集中第2相
- Cleveland Clinic Mercy Hospital, Canton · 21マイル先
- Aultman Health Foundation, Canton · 21マイル先
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- Aultman Health Foundation, Canton · 21マイル先
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- Aultman Health Foundation, Canton · 21マイル先
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2/3相
- Aultman Health Foundation, Canton · 21マイル先
GEMINI-NSCLC: NSCLC Biomarker Study
被験者募集中観察研究
- Aultman Hospital, Canton · 21マイル先
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
被験者募集中第1相
- Gabrail Cancer & Research Center, Canton · 21マイル先
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site 138, Canton · 21マイル先
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
被験者募集中第1/2相
- Gabrail Cancer Center Research, Canton · 21マイル先
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
被験者募集中第1/2相
- Gabrail Cancer Research Center, Canton · 21マイル先
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY120件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH56件の研究
- Washington, DC55件の研究
Akronにおける他の研究
- 肺がん16件の研究
- がん（全種類）13件の研究
- 乳がん13件の研究
- 前立腺がん9件の研究
- 急性骨髄性白血病8件の研究
- 悪性黒色腫8件の研究
- 小細胞肺がん8件の研究
- 転移性癌8件の研究
- 大腸癌8件の研究
- 脂肪肝7件の研究
- 子宮内膜がん6件の研究
- 卵巣がん6件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。